Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 1
1991 1
1994 1
1997 5
1998 4
2005 1
2006 1
2007 1
2008 1
2009 2
2010 9
2011 9
2012 9
2013 2
2014 4
2015 5
2016 5
2017 5
2018 7
2019 5
2020 12
2021 8
2022 11
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. You B, et al. Among authors: muzaffar m. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17. J Clin Oncol. 2022. PMID: 36252167 Free PMC article. Clinical Trial.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ. D'Alessio A, et al. Among authors: muzaffar m. Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8. Hepatology. 2022. PMID: 35313048 Free PMC article.
Eribulin-Associated Foot Drop.
Blair TF, Lambert K, Muzaffar M. Blair TF, et al. Among authors: muzaffar m. Am J Ther. 2019 Nov/Dec;26(6):e720-e722. doi: 10.1097/MJT.0000000000000881. Am J Ther. 2019. PMID: 30570505 No abstract available.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R. Vithayathil M, et al. Among authors: muzaffar m. Hepatol Int. 2023 Aug;17(4):904-914. doi: 10.1007/s12072-023-10491-3. Epub 2023 Apr 1. Hepatol Int. 2023. PMID: 37005953 Free PMC article.
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Joerg V, et al. Among authors: muzaffar m. Hepatol Commun. 2023 Oct 27;7(11):e0302. doi: 10.1097/HC9.0000000000000302. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37889520 Free PMC article.
Role of sacituzumab govitecan in solid tumors.
Veeraballi S, Khawar Z, Aslam HM, Muzaffar M. Veeraballi S, et al. Among authors: muzaffar m. J Oncol Pharm Pract. 2022 Oct;28(7):1617-1623. doi: 10.1177/10781552221092359. Epub 2022 Apr 11. J Oncol Pharm Pract. 2022. PMID: 35404158 Review.
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, Clark J, Koivunen JP, Macherla S, Jonnalagadda S, Polsani S, Jiwani RA, Hafiz M, Muzaffar M, Brunetti L, Stroud CRG, Walker PR, Wang K, Chung Y, Ruppin E, Lee SH, Yang LV, Pinato DJ, Lee JS, Cortellini A. Naqash AR, et al. Among authors: muzaffar m. J Immunother Cancer. 2023 Oct;11(10):e007310. doi: 10.1136/jitc-2023-007310. J Immunother Cancer. 2023. PMID: 37852738 Free PMC article.
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer.
Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Macherla S, et al. Among authors: muzaffar m. Int J Mol Sci. 2018 Nov 7;19(11):3505. doi: 10.3390/ijms19113505. Int J Mol Sci. 2018. PMID: 30405053 Free PMC article. Review.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R. Vithayathil M, et al. Among authors: muzaffar m. Liver Int. 2022 Nov;42(11):2538-2547. doi: 10.1111/liv.15405. Epub 2022 Sep 2. Liver Int. 2022. PMID: 35986902 Free PMC article.
116 results